Source-grounded facts extracted from Zivo Bioscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zivo Bioscience, Inc. incurred convertible notes of $250,000 with an accredited investor at 10% interest per annum maturing two years after the date of issuance.
“On July 8, 2025, Zivo Bioscience, Inc. (the“Company”) issued a Bridge Promissory Note in the principal amount of $250,000 and accompanying warrant to purchase 1,793 shares”
Laith Yaldoo was appointed as Director at Zivo Bioscience, Inc..
“On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.